It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Immunity acquired from a Covid infection provides strong, lasting protection against the most severe outcomes of the illness, according to research published Thursday in The Lancet — protection, experts say, that’s on par with what’s provided through two doses of an mRNA vaccine.
Infection-acquired immunity cut the risk of hospitalization and death from a Covid reinfection by 88% for at least 10 months, the study found.
“This is really good news, in the sense that protection against severe disease and death after infection is really quite sustained at 10 months,” said the senior study author, Dr. Christopher Murray, the director of the Institute for Health Metrics and Evaluation at the University of Washington.
NIH RESEARCH MATTERS
January 26, 2021
Lasting immunity found after recovery from COVID-19
At a Glance
The immune systems of more than 95% of people who recovered from COVID-19 had durable memories of the virus up to eight months after infection.
The results provide hope that people receiving SARS-CoV-2 vaccines will develop similar lasting immune memories after vaccination.
Novel Coronavirus SARS-CoV-2
Colorized scanning electron micrograph of a cell, isolated from a patient sample, that is heavily infected with SARS-CoV-2 virus particles (red). NIAID Integrated Research Facility, Fort Detrick, Maryland
After people recover from infection with a virus, the immune system retains a memory of it. Immune cells and proteins that circulate in the body can recognize and kill the pathogen if it’s encountered again, protecting against disease and reducing illness severity.
Pharma is the fourth-largest spender on TV ads in the U.S., with $6.6 billion spent over the past year. That’s according to MediaRadar’s annual study of TV ad spending
originally posted by: musicismagic
sadly here in japan those of elderly that are vaxxed over 4 times and ready for the 5th are in the hospital labled as severe case, which are amounting over 500 a day.
We found that protection against re-infection was high, with a mean pooled estimate greater than 82% for ancestral, alpha, beta, and delta variants (figure 2A; appendix p 9). By comparison, protection by past infection of earlier variants against re-infection by the omicron BA.1 variant was substantially reduced, with a pooled effectiveness of only 45·3%
The mean pooled protection from re-infection against symptomatic disease was 82% or greater for ancestral, alpha, beta, and delta variants, and was again substantially reduced for the omicron BA.1 variant (pooled estimate of 44·0%,
Only a small number of studies evaluated protection against omicron sublineages specifically (BA.2 and BA.4 and BA.5). Data by variant and outcome were in general not sufficient to conduct meta-analyses (table). Protection against omicron BA.2 and BA.4 and BA.5 was lower when the past infection was a pre-omicron variant than when the past infection was omicron.
For example, one study34 showed protection against omicron BA.2 re-infection of 47·0% (44·0–50·0) and another one32 showed protection against omicron BA.4 and BA.5 of 27·7%
Protection from past infection in comparison with that conferred by vaccination, however, must be weighed against the risks of severe morbidity and mortality associated with the initial infection. This balance of risk varies by the type of variant, with omicron for instance having less severe outcomes than delta,41, 42 and other risk factors associated with the individual, such as age and other comorbidities
originally posted by: putnam6
Wonder how long they sat on this...
They knew for 2 years...
2 years ago there was an NIH study that had a similar finding that everybody crapped on. See the link at the bottom 2 years ago NIH came to the same conclusions
Immunity acquired from a Covid infection is as protective as vaccination against severe illness and death, study finds
www.nbcnews.com...
Immunity acquired from a Covid infection provides strong, lasting protection against the most severe outcomes of the illness, according to research published Thursday in The Lancet — protection, experts say, that’s on par with what’s provided through two doses of an mRNA vaccine.
Infection-acquired immunity cut the risk of hospitalization and death from a Covid reinfection by 88% for at least 10 months, the study found.
“This is really good news, in the sense that protection against severe disease and death after infection is really quite sustained at 10 months,” said the senior study author, Dr. Christopher Murray, the director of the Institute for Health Metrics and Evaluation at the University of Washington.
www.nih.gov...
NIH RESEARCH MATTERS
January 26, 2021
Lasting immunity found after recovery from COVID-19
At a Glance
The immune systems of more than 95% of people who recovered from COVID-19 had durable memories of the virus up to eight months after infection.
The results provide hope that people receiving SARS-CoV-2 vaccines will develop similar lasting immune memories after vaccination.
Novel Coronavirus SARS-CoV-2
Colorized scanning electron micrograph of a cell, isolated from a patient sample, that is heavily infected with SARS-CoV-2 virus particles (red). NIAID Integrated Research Facility, Fort Detrick, Maryland
After people recover from infection with a virus, the immune system retains a memory of it. Immune cells and proteins that circulate in the body can recognize and kill the pathogen if it’s encountered again, protecting against disease and reducing illness severity.
originally posted by: quintessentone
a reply to: putnam6
The original study source from your posted source - it would appear the variants play a major role as to length of immunity and protection. There is a lot to unpack here. But it does state that protection from severe outcomes (hospitalization, death) is very high, that is if you don't have any underlying conditions that may turn into something deadly.
We found that protection against re-infection was high, with a mean pooled estimate greater than 82% for ancestral, alpha, beta, and delta variants (figure 2A; appendix p 9). By comparison, protection by past infection of earlier variants against re-infection by the omicron BA.1 variant was substantially reduced, with a pooled effectiveness of only 45·3%
The mean pooled protection from re-infection against symptomatic disease was 82% or greater for ancestral, alpha, beta, and delta variants, and was again substantially reduced for the omicron BA.1 variant (pooled estimate of 44·0%,
Only a small number of studies evaluated protection against omicron sublineages specifically (BA.2 and BA.4 and BA.5). Data by variant and outcome were in general not sufficient to conduct meta-analyses (table). Protection against omicron BA.2 and BA.4 and BA.5 was lower when the past infection was a pre-omicron variant than when the past infection was omicron.
For example, one study34 showed protection against omicron BA.2 re-infection of 47·0% (44·0–50·0) and another one32 showed protection against omicron BA.4 and BA.5 of 27·7%
Protection from past infection in comparison with that conferred by vaccination, however, must be weighed against the risks of severe morbidity and mortality associated with the initial infection. This balance of risk varies by the type of variant, with omicron for instance having less severe outcomes than delta,41, 42 and other risk factors associated with the individual, such as age and other comorbidities
www.thelancet.com...(22)02465-5/fulltext